Prevalence, severity, and related factors of anemia in HIV/AIDS patients

Journal of Research in Medical Sciences

Volumn 17, Issue 2, 2012, Pages 138-142

  Meidani, Mohsen ^a   Rezaei, Farshid ^a   Maracy, Mohammad Reza ^b   Avijgan, Majid ^a   Tayeri, Katayoun ^b  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

AIDS; Anemia; HIV positive

Indexed keywords

COTRIMOXAZOLE; CYANOCOBALAMIN; EFAVIRENZ; FLUCONAZOLE; HEMOGLOBIN; LAMIVUDINE; STAVUDINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AIDS PATIENT; ANEMIA; ARTICLE; CD4 LYMPHOCYTE COUNT; CROSS-SECTIONAL STUDY; DEATH; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG USE; EDUCATION; FEMALE; FERRITIN BLOOD LEVEL; FOLIC ACID BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HETEROSEXUALITY; HOMOSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IRAN; MAJOR CLINICAL STUDY; MALE; MICROCYTOSIS; NORMOCHROMIC NORMOCYTIC ANEMIA; PREVALENCE; RETICULOCYTE COUNT; RISK FACTOR; TOXOPLASMOSIS;

EID: 84866419670     PISSN: 17351995     EISSN: 17357136     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Zon LI, Arkin C, Groopman JE. Haematologic manifestations of the uman immunodeficiency virus (HIV). Br J Haematol 1987;66:251.
2. Volberding PA, Levine AM, Dieterich D, Mildvan D, Mitsuyasu R, Saag M, for the Anemia in HIV Working Group. Anemia in HIV Infection: Clinical impact and evidence-based management strategies. Clin Infect Dis 2004;38:1454-63.
3. Owiredu WKBA, Quaye L, Amidu A, Addai-Mensah O. Prevalence of anemia and immunological markers among Ghanaian HAART-naïve HIV-Patients and those on HAART. Afr Health Sci 2011;11:2-15.
4. Subbaraman R, Devaleenal B, Selvamuthu P, Yepthomi T, Solomon SS, Mayer KH, et al. Factors associated with anemia in HIV-infected individuals in southern India. Int J STD AIDS 2009;20:489-92.
5. Berhane K, Karim R, Cohen MH, et al. Impact of Highly Active Antiretroviral Therapy on Anemia and Relationship Between Anemia and Survival in a Large Cohort of HIV-Infected Women: Women's Interagency HIV Study. J Acquir Immune Defic Syndr 2004;37:1245.
6. Sullivan PS, Hanson DL, Chu SY, Jones JL, Ward JW. Epidemiology of anemia in human immunodeficiency virus (HIV)-infected persons: Results from the multistate adult and adolescent spectrum of HIV disease surveillance project. Blood 1998;91:301-8.
7. Buskin S, Sullivan P. Anemia and its treatment and outcomes in persons infected with human immunodeficiency virus. Transfussion 2004;44:826-32.
8. Moses A, Nelson J, Bagby G. The Influence of Human Immunodeficiency Virus-1 on hematopoiesis. Blood 1998;91:1479-95.
9. Koduri PR, Signa P, Nikolinakos P. Autoimmune hemolytic anemia in patients infected with human immunodeficiency virus-1. Am J Hematol 2002;70:174-6.
10. Belperio PS, Rhew DC. Prevalence and outcomes of anemia in individuals with human immunodeficiency virus: A systematic review of the literature. Am J Med 2004;116 Suppl 7A:27S-43S.
11. Bain BJ. Pathogenesis and pathophysiology of anemia in HIV infection. Curr Opin Hematol 1999;6:89-93.
12. Levine AM, Berhane K, Masri-Lavine L, Sanchez M, Young M, Augenbraun M, et al. Prevalence and correlates of anemia in a large cohort of HIV-infected women: Women's Interagency HIV Study. J Acquir Immune Defic Syndr 2001;26:28-35.
13. Semba RD, Shah N, Klein RS, Mayer KH, Schuman P, Vlahov D, et al. Prevalence and cumulative incidence of and risk factors for anemia in a multicenter cohort study of human immunodeficiency virus-infected and -uninfected women. Clin Infect Dis 2002;34:260-6.
14. Richman DD, Fischl MA, Grieco MH, Gottlieb MS, Volberding PA, Laskin OL, et al. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS related complex. A double-blind, placebo-controlled trial. N Engl J Med 1987;317:192-7.
15. Volberding PA, Lagakos SW, Koch MA, Pettinelli C, Myers MW, Booth DK, et al. Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases. N Engl J Med 1990;322:941-9.
16. Ssali F, Stohr W, Munderi P, Reid A, Walker AS, Gibb DM, et al. Prevalence, incidence and predictors of severe anaemia with zidovudine-containing regimens in African adults with HIV infection within the DART trial. Antivir Ther 2006;11:741-9.
17. Hoffmann CJ, Fielding KL, Charalambous S, Sulkowski MS, Innes C, Thio CL, et al. Antiretroviral therapy using zidovudine, lamivudine, and efavirenz in South Africa: tolerability and clinical events. AIDS 2008;22:67-74.
18. Hare CB. c and Disease in Adolescents and Adults, Table 3; Clinical Overview of HIV Disease. In: Peiperl L, Coffey S, Volberding PA, editors. HIV InSite Knowledge Base [textbook online]. San Francisco: UCSF Center for HIV Information; 2006. Available from: http:///www.hivinsite. ucsf.edu/InSite?page=kb-03-01-01. [Last accessed on 2006 Mar 23].
19. Kreuzer KA, Rockstroh JK. Pathogenesis and pathophysiology of anemia in HIV infection. Ann Hematol 1997;75:179-87.
20. Kiragga AN, Castelnuovo B, Nakanjako D, Manabe YC. Baseline severe anaemia should not preclude use of zidovudine in antiretroviral-eligible patients in resource-limited settings. J Int AIDS Soc 2010;13:42.
21. Moore RD, Creagh-Kirk T, Keruly J, Link G, Wang MC, Richman D, et al. Long-term safety and efficacy of zidovudine in patients with advanced humanimmunodeficiency virus disease. Zidovudine EpidemiologyStudy Group. Arch Intern Med 1991;151:981-6.
22. Ramezani A, Aghakhani A, Sharif MR, Banifazl M, Eslamifar A, Velayati AK. Anemia Prevalence and Related Factors in HIVInfected Patients: A Cohort Study. Iran J Pathol 2008;3:125-8.
23. Jam S, Ramezani A, Sabzvari D, Moradmand-Badie B, Seyedalinaghi SA, Jabbari H, et al. A cross-sectional study of anemia in human immunodeficiency virus-infected patients in Iran. Arch Iran Med 2009;12:145-50.
24. Agarwal D, Chakravarty J, Chaube L, Rai M, Agrawal NR, Sundar SH. High incidence of zidovudine induced anaemia in HIV infected patients in eastern India. Indian J Med Res 2010;132:386-9.
25. Mata-Marín JA, Gaytán-Martínez JE, Martínez-Martínez RE, Arroyo-Anduiza CI, Fuentes-Allen JL, Casarrubias-Ramirez M. Risk factors and correlates for anemia in HIV treatment-naïve infected patients: A cross-sectional analytical study. BMC Res Notes 2010;3:230.
26. Diallo DA, Baby M, Dembélé M, Kéita A, Sidibé AT, Cissé IA, et al. Frequency, risk factors, and prognostic value of anemia associated with HIV/AIDS in the adult in Mali. Bull Soc Pathol Exot 2003;96:123-7.
27. Wills TS, Nadler JP, Somboonwit C, Vincent A, Leitz G, Marino K, et al. Anemia prevalence and associated risk factors in a singlecenter ambulatory HIV clinical cohort. AIDS Read 2004;14:305-10, 313-5.
28. Mildvan D, Creagh T, Leitz G. Prevalence of anemia and correlation with biomarkers and specific antiretroviral regimens in 9690 human-immunodeficiency-virus-infected patients: findings of the Anemia Prevalence Study. Curr Med Res Opin 2007;23:343-55.
29. Moore RD, Forney D. Anemia in HIV-infected patients receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2002;29:54-7.
30. Dancheck B, Tang AM, Thomas AM, Smit E, Vlahov D, Semba RD. Injection drug use is an independent risk factor for iron deficiency and iron-deficiency anemia among HIV-seropositive and HIV-seronegative women. J Acquir Immune Defic Syndr 2005;40:198-201.
31. Johannessen A, Naman E, Ngowi BJ, Sandvik L, Matee MI, Aglen HE, et al. Predictors of mortality in HIV-infected patients starting antiretroviral therapy in a rural hospital in Tanzania. BMC Infect Dis 2008;8:52.
32. Saah AJ, Hoover DR, He Y, Kingsley LA, Phair JP. Factors influencing survival after AIDS: report from the Multicenter AIDS Cohort Study (MACS). J Acquir Immune Defic Syndr 1994;7:287-95.